Killer Cough Syrup Scandal: How a Contaminated Drug Claimed Dozens of Lives

In a devastating turn of events, at least 16 children in Chhindwara, Madhya Pradesh, have tragically lost their lives after consuming Coldrif cough syrup, a product found to be contaminated with diethylene glycol (DEG), a toxic industrial chemical. The syrup, manufactured by Sresan Pharmaceuticals in Tamil Nadu, was prescribed to children under the age of five, leading to acute kidney failure and subsequent deaths.

The Victims and Their Families

Among the young victims was Vikas Yaduvanshi, a four-year-old boy whose kidney biopsy confirmed acute tubular injury. Other children who succumbed to the effects of the contaminated syrup include Shivam Rathore (4), Vidhi Namita (3), and Yogita Thakre (2). These children were treated at the Government Medical College and Hospital (GMCH) in Nagpur, where the medical team administered Fomepizole, a drug typically used to treat methanol or ethylene glycol poisoning, to counteract the effects of DEG. 

The families of the victims are grappling with immense grief and loss. In an interview with NDTV, Chief Minister Mohan Yadav expressed deep sorrow over the incident and assured that the government would take stringent actions to prevent such tragedies in the future.

Timeline of Events

• August 2025: Children in Chhindwara begin exhibiting symptoms of acute kidney failure after consuming Coldrif cough syrup.
• September 2025: The number of affected children rises, prompting local health authorities to investigate the cause.
• October 2025: Laboratory tests confirm that Coldrif syrup contains dangerously high levels of DEG, leading to immediate actions by state authorities.

Investigations and Actions Taken

In response to the crisis, the Madhya Pradesh government has taken several measures:

• Suspension of Officials: Deputy Director Shobhit Costa and other senior officials from the state’s Food and Drug Administration have been suspended for their alleged negligence in monitoring the safety of pharmaceutical products.
• Seizure of Contaminated Stock: All existing stocks of Coldrif syrup have been seized, and a door-to-door campaign is underway to recover any remaining bottles from households.
• Criminal Charges: Dr. Praveen Soni, a government pediatrician who prescribed the syrup, has been arrested on charges of negligence causing death.
• Manufacturer Under Investigation: Sresan Pharmaceuticals, the manufacturer of Coldrif syrup, is under investigation for producing and distributing a contaminated product.

Additionally, the National Human Rights Commission (NHRC) has issued notices to the governments of Madhya Pradesh, Rajasthan, and Uttar Pradesh, directing them to investigate the allegations and submit reports within two weeks.

Regulatory Oversight and Public Health Implications

This incident has raised serious concerns about the regulatory oversight of pharmaceutical products in India. Experts emphasize the need for stringent quality control measures, regular inspections, and adherence to manufacturing guidelines to prevent such tragedies in the future. The presence of DEG (Diethylene Glycol) in medicinal products is a serious concern, as it can lead to kidney failure and other severe health issues.

Conclusion

The Coldrif cough syrup tragedy serves as a stark reminder of the vulnerabilities in India’s pharmaceutical sector. While immediate actions have been taken to halt the distribution of the contaminated product, long-term reforms are essential to ensure the safety and well-being of consumers. The incident calls for enhanced regulatory oversight, improved manufacturing practices, and greater accountability within the industry.